Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novus Therapeutics Inc (NVUS)

Novus Therapeutics Inc (NVUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,744
  • Shares Outstanding, K 12,967
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,070 K
  • 60-Month Beta 2.89
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.51
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.58
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/12/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.23
  • Number of Estimates 1
  • High Estimate -0.23
  • Low Estimate -0.23
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +53.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.48 +21.62%
on 12/04/19
0.84 -30.33%
on 12/10/19
-0.09 (-13.54%)
since 11/08/19
3-Month
0.40 +46.25%
on 10/16/19
0.84 -30.33%
on 12/10/19
-0.16 (-21.43%)
since 09/10/19
52-Week
0.40 +46.25%
on 10/16/19
5.21 -88.77%
on 02/27/19
-2.17 (-78.80%)
since 12/10/18

Most Recent Stories

More News
Novus Therapeutics to Participate in Two Investor Conferences

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company...

NVUS : 0.58 (+12.48%)
Novus Therapeutics Reports Third Quarter 2019 Financial Results

-- Data from ongoing phase 2a study C-006 expected in the first half of 2020 --

NVUS : 0.58 (+12.48%)
Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the U.S....

NVUS : 0.58 (+12.48%)
Novus Therapeutics to Participate in Two Upcoming Investor Conferences

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company...

NVUS : 0.58 (+12.48%)
Novus Therapeutics Reports Second Quarter 2019 Financial Results

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results...

NVUS : 0.58 (+12.48%)
Adynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB Market

Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and...

ADYX : 1.1000 (-8.33%)
NVUS : 0.58 (+12.48%)
Novus Therapeutics to Present OP0201 Data at the 20th International Symposium on Recent Advances in Otitis Media

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced...

NVUS : 0.58 (+12.48%)
Novus Therapeutics Reports First Quarter 2019 Financial Results

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced...

NVUS : 0.58 (+12.48%)
Novus Therapeutics Announces Closing of $10.7 Million Registered Direct Offering Priced At-the-Market

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced...

NVUS : 0.58 (+12.48%)
Novus Therapeutics Announces $10.7 Million Registered Direct Offering Priced At-the-Market

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced...

NVUS : 0.58 (+12.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade NVUS with:

Business Summary

Novus Therapeutics, Inc. is a pharmaceutical company. It focused on the acquisition, development and commercialization of ear, nose and throat products. The company's platform consists of OP-01 Foam Platform and OP-02 Surfactant Program. Novus Therapeutics, Inc., formerly known as Tokai Pharmaceuticals...

See More

Key Turning Points

2nd Resistance Point 0.99
1st Resistance Point 0.79
Last Price 0.58
1st Support Level 0.44
2nd Support Level 0.29

See More

52-Week High 5.21
Fibonacci 61.8% 3.37
Fibonacci 50% 2.81
Fibonacci 38.2% 2.24
Last Price 0.58
52-Week Low 0.40

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar